Ceftriaxone in the Management of Bipolar Depression
| Status: | Completed |
|---|---|
| Conditions: | Depression, Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/2/2016 |
| Start Date: | September 2007 |
| End Date: | October 2010 |
| Contact: | Kathleen Maloney, BA |
| Email: | kathleen.maloney@yale.edu |
| Phone: | 203-974-7496 |
Modulation of Glutamatergic Neurotransmission in the Treatment of Bipolar Depression
We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient,
placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar
disorder, currently depressed, who have failed to respond to conventional treatments.
placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar
disorder, currently depressed, who have failed to respond to conventional treatments.
Inclusion Criteria:
- DSM-IV diagnosis of bipolar disorder
- Presence of a current major depressive episode on the SCID
- Score of 17 or greater on the HDRS
- Failure to respond to two previous medication trials
- Capable of giving voluntary written consent
Exclusion Criteria:
- Hypersensitivity to penicillin or cephalosporin, resulting in anaphylaxis
- Significant current substance dependence/abuse within 3 months preceding the trial
- Significant history of intravenous drug abuse
- Active suicidal ideation
- Pregnant/lactating mothers
- Significant medical history
- Patients on anticoagulation treatment
- Patients who test positive for HIV or Hep B or C
We found this trial at
1
site
Yale University School of Medicine Founded in 1810, the Yale School of Medicine is a...
Click here to add this to my saved trials
